Grifols takes a nice €100M slice for Alzheimer’s from EU €315 Billion Investment Offensive

30/10/2015 - 2 minutes

A huge European action for the next three following years is the European Fund for Strategic Investments (aka the Juncker plan). This consists of a €315 billion Investment Plan to “get Europe growing and more people back to work” (as written on Europa’s website).

2000px-Grifols.svgThe Barcelonan Grifols (Spain) is one of the first companies to receive its slice from the European Investment Bank. Grifols is a leader in plasma protein manufacturing and a pioneer in the research and development of alternative therapeutic application of these products.

The loan will mostly support their R&D program for alternative use of hematological biologicals. Signed on the 28th of October, the €100M loan has certain conditions, including a fixed interest rate, a tenor of ten years and a two year grace period.

Plasma proteins can be used for the same target across a wide range of different diseases. For example, one indication in the Central nervous system includes Alzheimer’s disease,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!